Details
Stereochemistry | RACEMIC |
Molecular Formula | C25H27ClN2 |
Molecular Weight | 390.948 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=CC(CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(Cl)C=C4)=C1
InChI
InChIKey=OCJYIGYOJCODJL-UHFFFAOYSA-N
InChI=1S/C25H27ClN2/c1-20-6-5-7-21(18-20)19-27-14-16-28(17-15-27)25(22-8-3-2-4-9-22)23-10-12-24(26)13-11-23/h2-13,18,25H,14-17,19H2,1H3
DescriptionSources: http://www.drugbank.ca/drugs/DB00737Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/meclizine.html
Sources: http://www.drugbank.ca/drugs/DB00737
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/meclizine.html
Meclizine, a piperazine-derivative H1-receptor antagonist similar to buclizine, cyclizine, and hydroxyzine, is used as an antivertigo/antiemetic agent. Meclizine is used in the management of nausea, vomiting, and dizziness associated with motion sickness and vertigo in diseases affecting the vestibular apparatus. Along with its actions as an antagonist at H1-receptors, meclizine also possesses anticholinergic, central nervous system depressant, and local anesthetic effects. Meclizine depresses labyrinth excitability and vestibular stimulation and may affect the medullary chemoreceptor trigger zone. It is sold under the brand names Bonine, Bonamine, Antivert, Postafen, Sea Legs, and Dramamine II.
CNS Activity
Sources: http://www.drugbank.ca/drugs/DB00737
Curator's Comment: central nervous system depressant
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL340 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26239802 |
|||
Target ID: CHEMBL3401 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26239802 |
|||
Target ID: Q922E4 Gene ID: 68671.0 Gene Symbol: Pcyt2 Target Organism: Mus musculus (Mouse) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24142790 |
31.0 µM [Ki] | ||
Target ID: CHEMBL231 Sources: http://www.drugbank.ca/drugs/DB00737 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ANTIVERT Approved UseEffective: Management of nausea and vomiting, and dizziness associated with motion sickness.
Possibly Effective: Management of vertigo associated with diseases affecting the vestibular system. Launch Date2012 |
|||
Primary | ANTIVERT Approved UseEffective: Management of nausea and vomiting, and dizziness associated with motion sickness.
Possibly Effective: Management of vertigo associated with diseases affecting the vestibular system. Launch Date2012 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
99.43 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21903894/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
MECLIZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
564.03 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21903894/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
MECLIZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.24 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21903894/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
MECLIZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
25 mg 2 times / day multiple, oral Recommended Dose: 25 mg, 2 times / day Route: oral Route: multiple Dose: 25 mg, 2 times / day Sources: |
unhealthy, 5-10 n = 6 Health Status: unhealthy Condition: Achondroplasia Age Group: 5-10 Sex: M+F Population Size: 6 Sources: |
|
25 mg single, oral Recommended |
unhealthy, 6-10 n = 6 Health Status: unhealthy Condition: Achondroplasia Age Group: 6-10 Sex: M+F Population Size: 6 Sources: |
|
100 mg multiple, oral (total daily dose) Recommended Dose: 100 mg Route: oral Route: multiple Dose: 100 mg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Vertigo Sources: Page: p.1 |
Other AEs: Drowsiness... Other AEs: Drowsiness Sources: Page: p.1 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Drowsiness | 100 mg multiple, oral (total daily dose) Recommended Dose: 100 mg Route: oral Route: multiple Dose: 100 mg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Vertigo Sources: Page: p.1 |
PubMed
Title | Date | PubMed |
---|---|---|
Drug-induced extrapyramidal signs in chronic liver disease--a case report. | 1977 |
|
Clofibrate myopathy: a case report and a review of the literature. | 1986 Feb |
|
Memory loss, confusion, and disorientation in an elderly woman taking meclizine. | 1987 May |
|
Pentoxifylline-induced musical hallucinations. | 1993 Aug |
|
Relationship between vitamin use, smoking, and nausea and vomiting of pregnancy. | 2003 Oct |
|
Auditory hallucinations elicited by combined meclizine and metaxalone use at bedtime. | 2004 Nov |
|
Use of antiemetic drugs during pregnancy in Sweden. | 2005 Dec |
|
Withdrawal symptoms after discontinuation of transdermal scopolamine therapy: treatment with meclizine. | 2009 Nov 15 |
|
Multi-species analyses of direct activators of the constitutive androstane receptor. | 2011 Oct |
|
FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1. | 2013 Sep 5 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/meclizine.html
Usual Adult Dose for Vertigo
-25 to 100 mg orally per day in divided doses
Usual Adult Dose for Motion Sickness
-Initial Dose: 25 to 50 mg orally 1 hour before travel
-Maintenance Dose: Repeat dose every 24 hours if needed
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24142790
50 uM meclizine inhibited respiratory growth of human skin fibroblasts
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
||
|
WHO-ATC |
R06AE05
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
||
|
WHO-ATC |
R06AE55
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
||
|
WHO-VATC |
QR06AE55
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
||
|
LIVERTOX |
NBK547895
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
||
|
WHO-VATC |
QR06AE05
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
||
|
NDF-RT |
N0000178372
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
||
|
NCI_THESAURUS |
C267
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
||
|
NDF-RT |
N0000009034
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
||
|
NDF-RT |
N0000009034
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6676
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
PRIMARY | RxNorm | ||
|
DB00737
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
PRIMARY | |||
|
4034
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
PRIMARY | |||
|
MECLOZINE
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
PRIMARY | |||
|
CHEMBL1623
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
PRIMARY | |||
|
SUB08685MIG
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
PRIMARY | |||
|
C61610
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
PRIMARY | |||
|
Meclizine
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
PRIMARY | |||
|
3L5TQ84570
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
PRIMARY | |||
|
1649
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
PRIMARY | |||
|
169189
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
PRIMARY | |||
|
100000081967
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
PRIMARY | |||
|
m7118
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
PRIMARY | Merck Index | ||
|
2757
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
PRIMARY | |||
|
209-323-3
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
PRIMARY | |||
|
3L5TQ84570
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
PRIMARY | |||
|
D008468
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
PRIMARY | |||
|
3113
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
PRIMARY | |||
|
204
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
PRIMARY | |||
|
DTXSID0023242
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
PRIMARY | |||
|
569-65-3
Created by
admin on Fri Dec 15 17:17:01 GMT 2023 , Edited by admin on Fri Dec 15 17:17:01 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)